Among these, NF-related QSOX1 and CAF-related EDIL3 were validated in an independent validation cohort of 10 CRC patients, in whole tissue immunohistochemistry (IHC) and in patient plasma-derived EXOs (pEXOs). This evidence concerns the gene EDIL3 and colorectal carcinoma.